New York, NY – November 12, 2024 – Yamo Pharmaceuticals is pleased to announce that its late-breaking abstract, titled “Catecholamine Modulation Using the Tyrosine Hydroxylase Inhibitor L1-79 for the Treatment of Socialization Impairments in Adolescents and Young Adults with Autism Spectrum Disorders,” has been accepted for presentation at the 2024 Child Neurology Society (CNS) Conference.
The abstract presents compelling findings from a Phase 2, multi-center, randomized, double-blind, placebo-controlled crossover study evaluating the efficacy, safety, and tolerability of L1-79 in adolescents and young adults with Autism Spectrum Disorder (ASD). The study demonstrated statistically significant and clinically meaningful improvements in socialization, as measured by the Vineland Adaptive Behavior Scale, Third Edition (Vineland-3) Socialization Domain. Specifically, L1-79 showed a difference compared to placebo of 7.94 points (p=0.0115) in the Vineland-3 Socialization Standard Score. Additionally, significant improvements were observed in key secondary measures, including the Clinical Global Impression of Severity (CGI-S) and the Caregiver Global Impression of Change of 3 Most Bothersome Symptoms of ASD (CGI-3P). L1-79 was well-tolerated, with no serious adverse events or adverse events leading to withdrawal from the trial.
“We are excited to share these compelling results with the neurology community,” said J. Thomas Megerian, MD, PhD, Chief Medical Officer at Yamo Pharmaceuticals. “The acceptance of this late-breaking abstract underscores the potential of L1-79 to address the core symptoms of ASD, offering hope to patients and their families.”
For more information about the study, please visit the clinical trial listing at NCT05067582.
Access the Poster:
The full poster presentation, detailing these findings, can be accessed through the link below:
